Summary & Overview
HCPCS Level II C9145: Aprepitant (Aponvie) Injection, 1 mg
HCPCS Level II code C9145 denotes a 1 mg injection of aprepitant (brand name Aponvie). The code captures administration of a commonly used NK1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting and other clinical scenarios where aprepitant is indicated. As an HCPCS Level II product code for a packaged injectable medication, C9145 matters nationally for outpatient oncology and infusion billing, inventory tracking, and payer coverage determinations.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role, typical sites of service (outpatient infusion centers, hospital outpatient departments, and physician offices), and the billing context for a unitized injectable drug code. The publication outlines benchmarks for utilization and billing practice (where available), typical modifiers used with injectable drug administration, and policy or coverage considerations that commonly affect payment and prior authorization for antiemetic agents.
This summary equips coding professionals, revenue cycle staff, and clinical administrators with the essential framing of C9145 to support correct billing, inventory planning, and payer communication at a national level. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9145 describes an injection of aprepitant (Aponvie), 1 mg. This code represents a single-unit measure for administration of the antiemetic agent aprepitant, commonly used in chemotherapy-induced nausea and vomiting prophylaxis and related supportive oncology care.
Service Type: Parenteral injection (medication administration)
Typical Site of Service: Outpatient infusion center or clinic; may also be used in hospital outpatient departments or physician offices where injected antiemetic therapy is administered.
Clinical & Coding Specifications
Clinical Context
An adult oncology patient receiving antiemetic therapy in an outpatient infusion center for prevention of chemotherapy-induced nausea and vomiting. Aprepitant (C9145) is administered as an injectable agent, typically as part of a multi-drug antiemetic regimen for moderate to highly emetogenic chemotherapy. The typical workflow: pre-visit order entry by the oncologist, verification of the chemotherapy and antiemetic regimen by the pharmacist, patient arrival and assessment by nursing (vital signs, IV access), preparation of the injectable aprepitant dose by pharmacy, nurse administration via IV push or infusion, post-administration observation for infusion reaction or adverse effects, and documentation of lot number, route, dose (milligrams billed using C9145 per 1 mg unit), and any modifier as required for billing. Typical site of service is an outpatient infusion center or hospital outpatient department. Typical patient scenario: a 58-year-old female with breast cancer receiving a highly emetogenic chemotherapy regimen scheduled for premedication with an aprepitant injectable dose to reduce acute and delayed nausea and vomiting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard reporting | Use when no special circumstance applies and service is billed as usual. |